Heading a team responsible for clinical operations systems.

The Data Assets and Insights Solutions subfunction, DAIS, consists of a team of dedicated computer and data scientists which combine deep R&D process and domain expertise (biology, chemistry, pharmacy, etc) with advanced computational expertise (software engineering, natural language processing, scalable architectures, bio- & chem-informatics, data integration & visualization, etc). We integrate, enrich and harmonize large scientific datasets to build foundational data assets which are used by the R&D organization and our team to build insights solutions. They address key R&D challenges to improve speed, quality and probability of success of our R&D pipeline. Selected business critical tasks within R&D we are focusing on: - Target identification including holistic assessment - Disease understanding including precision medicine - Pipeline evaluation (therapeutic potential and risks) - Modality selection including identification of tool compounds - Identification of collaboration and in-licensing opportunities For more information contact: Wolfgang Thielemann. Artwork: Licensed pictures.

Understanding how compounds affect the disease biology of patients, and which potential side effects could be expected, is one of the core challenges in drug discovery. Transcriptomics (RNA-seq) allows us to measure these compound effects via an unbiased readout of gene expression changes. While „conventional“ analysis of RNA-seq data yields insights into individual compound effects and similarities, deeper connections between principles of compound structure and transcriptome effect elude us. Insights into this connection would help us support project teams with data-driven decision making on compounds. In this pilot, we are bringing together a cross-functional team of colleagues from LST, CMD, SyMOL and DS&AI to tackle this challenge and build a toolkit to enable understanding of ​how compound structure relates to complex gene expression patterns​ and to explore common themes amongst structures or shared off-target/general perturbation effects. This toolbox will become the starting point for other efforts aimed at leveraging multi-omics data in understanding compound mechanism of actions. Artwork created using Stable Diffusion.

The Applied Machine Learning Group (AML) strives for the application of a data-driven approach to drug research and development by developing and utilizing best-in-class machine learning (ML) models to optimize R&D processes. The implementation of ML algorithms accelerates drug discovery and a platform to monitor and self-train models enables portfolio view of our capabilities, allowing us to become more focused. We envision to work in a fast-paced setting, we expect to fail quickly and adapt swiftly, all while expanding your ML capabilities. We also believe in making the right choices not only for our immediate team but decisions to build solutions catered to broader R&D. The success at AML will be measured by bucketing the benefit of the developed capability into one or more of these three buckets, (1) Savings in time (2) Savings in cost (3) Generation of new insights

Scientific work in Pharma R&D requires a reliable high-quality body of data and knowledge. Bayer Pharma R&D has an extremely large amount of scientific data. The use of a Data Catalog significantly improves the findability of data and serves as a key pillar in the implementation of a comprehensive data strategy.

The Proprietary Information Management team, PIM, takes care of processes and systems related to either Compliance or Data Governance. Please talk to us if you need help with some cross-functional or collaboration-related topic or if you are interested to learn more about compound-related processes, compliance checks, lab notebook systems and similar things. For more information contact: Friederike Stoll.

The SCLM4Future project together with the PRINCE (Preclinical Information Center) project as well as the CONDAS (Connecting Data for Science) team is an excellent example for a successful cross-functional collaboration between CD&O, RED preMed and DS&AI within Research & Development but also between Platform IT and external partners. Together the team achieved to overcome legacy manual processes, redundant maintenance work, and functional silos by introducing new digital solutions and concepts with a strong collaborative mindset. The newly released SCLM 2.0 (Standard Codelist Maintenance) & PTO (Preclinical Terminology and Ontology) systems will enable our organization to improve the quality of controlled terminologies with regards to standard codelists and codes while reducing maintenance time and effort. This will have a positive impact on the code/codelist consistency across clinical and preclinical, as well as the compliance to regulatory requirements (e.g. CDISC (Clinical Data Interchange Standard Consortium) Controlled Terminology). The approach to share our knowledge as well as our efforts across functions will be an important step to archive our goals to increase data quality, interoperability and reusability – or to make a long story short: to make our data even more FAIR. For more information contact: Daniela Bergann.

Lucky you! It's not every day that you meet the one and only Hans, leader of the amazing Value, Engagement & Training team, passionately driving digital transformation, strategy, value, portfolio and continuous learning in Bayer Pharma R&D. Situational leadership, empathy, collaboration and transparency are among his core values. In his personal life he runs marathons, trains & coaches a youth football team, works in the garden, walks with his dog and enjoys his Italian/Dutch family. Pleased to meet you :-)